Novo stock split conditional on U.S. approval for Tresiba
COPENHAGEN Jan 31 (Reuters) - Danish group Novo Nordisk said an approval of insulin Tresiba in the Unites States was a condition for a decision to split the company's share.
"It is one condition that must be met. Whether there are multiple conditions, we keep to ourselves," chairman Stone Scheiby told Reuters on Thursday.
On Thursday, Novo nudged up its sales and profit forecasts for this year after strong sales of modern insulins and diabetes drug Victoza helped deliver a 16 percent rise in fourth-quarter revenue. (Reporting by Mette Fraende; Editing by Dan Lalor)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Pope Francis named Time's Person of the Year |
- Uruguay becomes first country to legalize marijuana trade
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls